TGFB1 and neoplasm: TGF-β and IL6R are immunosuppressive factors in the tumor microenvironment, so depleting these soluble factors could help improve the efficacy of cancer immunotherapy treatments, such as immune checkpoint blockade and CAR-T therapy (23).